BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 21827980)

  • 1. [IMiDs in hematology].
    Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
    Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Thalidomide: mechanisms of action and new insights in hematology].
    Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
    Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
    Wiernik PH
    Curr Treat Options Oncol; 2009 Apr; 10(1-2):1-15. PubMed ID: 19016330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application and biology of immunomodulatory drugs (IMiDs) in cancer.
    Pan B; Lentzsch S
    Pharmacol Ther; 2012 Oct; 136(1):56-68. PubMed ID: 22796518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
    Lacy MQ; Tefferi A
    Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
    Jiménez Lozano I; Juárez Jiménez JC
    Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
    Vallet S; Witzens-Harig M; Jaeger D; Podar K
    Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMiDs: a novel class of immunomodulators.
    Knight R
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances of IMiDs in cancer therapy.
    Li S; Gill N; Lentzsch S
    Curr Opin Oncol; 2010 Nov; 22(6):579-85. PubMed ID: 20689431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lenalidomide in hematological malignancies---review].
    Jin X; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):205-9. PubMed ID: 22391198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
    Schafer PH
    Expert Opin Pharmacother; 2012 Jul; 13(10):1541-2. PubMed ID: 22646699
    [No Abstract]   [Full Text] [Related]  

  • 12. The evolving role of lenalidomide in the treatment of hematologic malignancies.
    Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2007 Mar; 8(4):497-509. PubMed ID: 17309344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunomodulatory drugs (IMiDs)].
    Oshima K; Ichinohe T
    Nihon Rinsho; 2014 Jun; 72(6):1130-5. PubMed ID: 25016816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
    Raza S; Safyan RA; Lentzsch S
    Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory drugs.
    Crane E; List A
    Cancer Invest; 2005; 23(7):625-34. PubMed ID: 16305990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes.
    Castelli R; Cassin R; Cannavò A; Cugno M
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):1-7. PubMed ID: 23153925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
    Fuchs O
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
    Srkalovic G; Hussein M
    Bosn J Basic Med Sci; 2009 Oct; 9 Suppl 1(Suppl 1):S3-S10. PubMed ID: 19912117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.